Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million... Read more.
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq:... Read more.
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced... Read more.
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Grew full-year revenue to between $515 million and $517 million, an increase of 16% SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq:... Read more.
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product... Read more.
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
Preliminary Full-Year 2025 Product Revenue of $206.1 Million Full-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth,... Read more.
Vibe Retail POS Sets the Standard for Retail-Focused Point-of-Sale Technology
BROOKLYN, N.Y.–(BUSINESS WIRE)–#CloudPOS–As point-of-sale platforms increasingly expand to support restaurants, services, and multiple verticals,... Read more.
Direct Source Highlights the Hottest Retail Technology Innovations at NRF Big Show 2026
AI-driven checkout, RFID-powered experiences, sustainable business systems and enhanced in-store engagement tools will drive the in-store experience MINNEAPOLIS... Read more.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in... Read more.
Debiopharm Deploys Genialis Software to Advance AI-Based Biomarker Discovery
Genialis Expressions empowers drug development teams to make confident decisions by unifying workflows and standardizing omics data for enterprise-grade clarity... Read more.